Advertisement

Medical Oncology

, Volume 27, Issue 2, pp 255–261 | Cite as

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

  • Ledu Zhou
  • Yun Huang
  • Jingdong Li
  • Zhiming WangEmail author
Original Paper

Abstract

Objective The mammalian target of rapamycin (mTOR) pathway, an important regulator of multiple cellular functions including proliferation, differentiation, tumorigenesis, and apoptosis, is up-regulated in many cancers. It has achieved considerable importance. This study was conducted to determine the status of the mTOR pathway in human hepatocellular carcinoma (HCC) and to investigate its relationship with the prognosis of HCC. Methods PTEN, pAkt, p27, and pS6 expression in cryo-sections gathered from 528 cases with HCC by the method of immunohistochemistry. Kaplan–Meier survival and Cox regression analyses were performed to evaluate the prognosis of HCC. Results The mTOR pathway was more significantly altered in high-grade tumors, and tumors with poor prognostic features. Especially, pAkt and cytoplasmic p27 expression showed the strongest associations with pathological parameters of HCC. Statistical analysis showed that HCC patients expressing pAkt, PTEN, cytoplasmic p27, and pS6 have different overall survival rates relative to those not expressing these proteins. Cox multi-factor analysis showed that tumor differentiation (P = 0.006), vascular invasion (P = 0.028), TNM stage (P = 0.005), pAkt (P = 0.021), PTEN (P = 0.003), p27 (P = 0.018) and pS6 (P = 0.002) were independent prognosis factors for HCC. Conclusion: Expression of the mTOR pathway components, which are related with the transferability and invasive capacity of HCC cells, may be used as prognostic indicators in HCC.

Keywords

Hepatocellular carcinoma mTOR S6 Akt PTEN p27 Prognosis 

Abbreviation

mTOR

Mammalian target of rapamycin

HCC

Hepatocellular carcinoma

References

  1. 1.
    Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87. doi: 10.1038/nrc1934.CrossRefPubMedGoogle Scholar
  2. 2.
    Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339–46. doi: 10.1038/ng0802-339.CrossRefPubMedGoogle Scholar
  3. 3.
    Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6:107–16. doi: 10.1038/nrc1799.CrossRefPubMedGoogle Scholar
  4. 4.
    Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19–24. doi: 10.1038/ng1494.CrossRefPubMedGoogle Scholar
  5. 5.
    Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005;11:353–61. doi: 10.1016/j.molmed.2005.06.007.CrossRefPubMedGoogle Scholar
  6. 6.
    Hardie DG. The AMP-activated protein kinase pathway new players upstream and downstream. J Cell Sci. 2004;117:5479–87. doi: 10.1242/jcs.01540.CrossRefPubMedGoogle Scholar
  7. 7.
    Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol. 2005;17:158–66. doi: 10.1016/j.ceb.2005.02.008.CrossRefPubMedGoogle Scholar
  8. 8.
    Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005;56:47–60. doi: 10.1016/j.critrevonc.2004.09.009.CrossRefPubMedGoogle Scholar
  9. 9.
    Shaw RJ, Bardeesy N, Manning BD. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6(1):91–9. doi: 10.1016/j.ccr.2004.06.007.CrossRefPubMedGoogle Scholar
  10. 10.
    Chan S. Targeting the mTOR: a new approach to treating cancer. Br J Cancer. 2004;91:1420–4. doi: 10.1038/sj.bjc.6602162.CrossRefPubMedGoogle Scholar
  11. 11.
    Ishak KG, Anthony PP, Sobin LH. Nonepithelial tumors. In: Ishak KG, editor. Histological typing of tumors of the liver. World Health Organization International Classification of Tumors. Berlin: Springer; 1994. pp. 22–7.Google Scholar
  12. 12.
    Wittekind C. Pitfalls in the classification of liver tumors. Pathologe. 2006;27:289–93. doi: 10.1007/s00292-006-0834-1.CrossRefPubMedGoogle Scholar
  13. 13.
    Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586–93. doi: 10.1200/JCO.2006.09.4565.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707–16. doi: 10.1200/JCO.2007.15.6521.CrossRefPubMedGoogle Scholar
  15. 15.
    Pantuck AJ, Seligson DB, Klatte T. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer. 2007;109:2257–67. doi: 10.1002/cncr.22677.CrossRefPubMedGoogle Scholar
  16. 16.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76. doi: 10.1053/j.gastro.2007.04.061.CrossRefPubMedGoogle Scholar
  17. 17.
    Blum H. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391–400.PubMedGoogle Scholar
  18. 18.
    Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155:323–33. doi: 10.1093/aje/155.4.323.CrossRefPubMedGoogle Scholar
  19. 19.
    Hashimoto E, Taniai M, Kaneda H, Tokushige K, Hasegawa K, Okuda H. Comparison of hepatocellular carcinoma patients with alcoholic liver disease and nonalcoholic steatohepatitis. Alcohol Clin Exp Res. 2004;28:164S–8S.PubMedGoogle Scholar
  20. 20.
    Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H. JACC Study Group. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer. 2005;93:607–10. doi: 10.1038/sj.bjc.6602737.CrossRefPubMedGoogle Scholar
  21. 21.
    Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007;47:506–13. doi: 10.1016/j.jhep.2007.03.015.CrossRefPubMedGoogle Scholar
  22. 22.
    Aravalli RN, Steer CJ, Cressman ENK. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008; 2047–63.Google Scholar
  23. 23.
    Zhou X, Tan M, Stone Hawthorne V. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 over expression predicts tumor progression in breast cancers. Clin Cancer Res. 2004;10:6779–88. doi: 10.1158/1078-0432.CCR-04-0112.CrossRefPubMedGoogle Scholar
  24. 24.
    Luo J, Manning BD, Cantley LC. Targeting the PI3 K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257–62. doi: 10.1016/S1535-6108(03)00248-4.CrossRefPubMedGoogle Scholar
  25. 25.
    Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335–48. doi: 10.1038/nrc1362.CrossRefPubMedGoogle Scholar
  26. 26.
    Pene F, Claessens Y-E, Muller O. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002;21:6587–97. doi: 10.1038/sj.onc.1205923.CrossRefPubMedGoogle Scholar
  27. 27.
    Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–45. doi: 10.1101/gad.1212704.CrossRefPubMedGoogle Scholar
  28. 28.
    Neshat MS, Mellinghoff IK, Tran C. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 2001;98:10314–9. doi: 10.1073/pnas.171076798.CrossRefPubMedGoogle Scholar
  29. 29.
    Wu FY, Wang SE, Sanders ME. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res. 2006;66:2162–72. doi: 10.1158/0008-5472.CAN-05-3304.CrossRefPubMedGoogle Scholar
  30. 30.
    Viglietto G, Motti ML, Bruni P. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002;8:1136–44. doi: 10.1038/nm762.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Ledu Zhou
    • 1
  • Yun Huang
    • 1
  • Jingdong Li
    • 1
  • Zhiming Wang
    • 1
    Email author
  1. 1.General Surgery Department of XiangYa HosptialCentral South UniversityChangshaChina

Personalised recommendations